Abstract
Over the past 25 years there have been thousands of published reports describing applications of antisense nucleic acid derivatives for targeted inhibition of gene function. The major classes of antisense agents currently used by investigators for sequence-specific mRNA knockdowns are antisense oligonucleotides (ODNs), ribozymes, DNAzymes and RNA interference (RNAi). Whatever the method, the problems for effective application are remarkably similar: efficient delivery, enhanced stability, minimization of off-target effects and identification of sensitive sites in the target RNAs. These challenges have been in existence from the first attempts to use antisense research tools, and need to be met before any antisense molecule can become widely accepted as a therapeutic agent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Fire, A. et al. Potent and specific genetic interference by double-stranded RNA in C. elegans. Nature 391, 806–811 (1998).
Elbashir, S.M. et al. Duplexes of 21-nucleotide RNA s mediate RNA interference in cultured mammalian cells. Nature 411, 494–498 (2001).
Caplen, N.J., Parrish, S., Imani, F., Fire, A. & Morgan, R.A. Specific inhibition of gene expression by small double-stranded RNA s in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA 98, 9742–9747 (2001).
Stephenson, M.L. & Zamecnik, P.C. Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide. Proc. Natl. Acad. Sci. USA 75, 285–288 (1978).
Zamecnik, P.C. & Stephenson, M.L. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc. Natl. Acad. Sci. USA 75, 280–284 (1978).
Crooke, S.T. Molecular mechanisms of action of antisense drugs. Biochem. Biophys. Acta. 1489, 31–44 (1999).
Branch, A.D. A hitchhiker's guide to antisense and nonantisense biochemical pathways. Hepatology 24, 1517–1529 (1996).
Dias, N. & Stein, C.A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347–355 (2002).
Stein, C.A. & Cohen, J.S. Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res. 48, 2659–2668 (1988).
Zon, G. Innovations in the use of antisense oligonucleotides. Ann. NY Acad. Sci. 616, 161–172 (1990).
Kruger, K. et al. Self-splicing RNA: autoexcision and autocyclization of the ribosomal RNA intervening sequence of Tetrahymena. Cell 31, 147–157 (1982).
Bevilacqua, P.C. & Turner, D.H. Comparison of binding of mixed ribose-deoxyribose analogues of CUCU to a ribozyme and to GGAGAA by equilibrium dialysis: evidence for ribozyme specific interactions with 2' OH groups. Biochemistry 30, 10632–10640 (1991).
Guerrier-Takada, C., Gardiner, K., Marsh, T., Pace, N. & Altman, S. The RNA moiety of ribonuclease P is the catalytic subunit of the enzyme. Cell 35, 849–857 (1983).
Costa, M. & Michel, F. Frequent use of the same tertiary motif by self-folding RNAs. EMBO J. 14, 1276–1285 (1995).
Hutchins, C.J., Rathjen, P.D., Forster, A.C. & Symons, R.H. Self-cleavage of plus and minus RNA transcripts of avocado sunblotch viroid. Nucleic Acids Res. 14, 3627–3640 (1986).
Buzayan, J.M., McNinch, J.S., Schneider, I.R. & Bruening, G. A nucleotide sequence rearrangement distinguishes two isolates of satellite tobacco ringspot virus RNA. Virology 160, 95–99 (1987).
Buzayan, J.M., Hampel, A. & Bruening, G. Nucleotide sequence and newly formed phosphodiester bond of spontaneously ligated satellite tobacco ringspot virus RNA. Nucleic Acids Res. 14, 9729–9743 (1986).
Kumar, P.K. et al. Random mutations to evaluate the role of bases at two important single- stranded regions of genomic HDV ribozyme. Nucleic Acids Res. 20, 3919–3924 (1992).
Saville, B.J. & Collins, R.A. A site-specific self-cleavage reaction performed by a novel RNA in Neurospora mitochondria. Cell 61, 685–696 (1990).
Wilson, D.S. & Szostak, J.W. In vitro selection of functional nucleic acids. Annu. Rev. Biochem. 68, 611–647 (1999).
Szostak, J.W. Enzymatic activity of the conserved core of a group I self-splicing intron. Nature 322, 83–86 (1986).
Jones, J.T., Lee, S.W. & Sullenger, B.A. Trans-splicing reactions by ribozymes. Methods Mol. Biol. 74, 341–348 (1997).
Sullenger, B.A. & Cech, T.R. Ribozyme-mediated repair of defective mRNA by targeted, trans-splicing. Nature 371, 619–622 (1994).
Lan, N. et al. Enhancing RNA repair efficiency by combining trans-splicing ribozymes that recognize different accessible sites on a target RNA. Mol. Ther. 2, 245–255 (2000).
Lan, N., Howrey, R.P., Lee, S.W., Smith, C.A. & Sullenger, B.A. Ribozyme-mediated repair of sickle beta-globin mRNAs in erythrocyte precursors. Science 280, 1593–1596 (1998).
Watanabe, T. & Sullenger, B.A. Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc. Natl. Acad. Sci. USA 97, 8490–8494 (2000).
Phylactou, L.A., Darrah, C. & Wood, M.J. Ribozyme-mediated trans-splicing of a trinucleotide repeat. Nat. Genet. 18, 378–381 (1998).
Kurz, J.C. & Fierke, C.A. Ribonuclease P: a ribonucleoprotein enzyme. Curr. Opin. Chem. Biol. 4, 553–558 (2000).
Forster, A.C. & Altman, S. External guide sequences for an RNA enzyme. Science 249, 783–786 (1990).
Ikawa, Y., Shiraishi, H. & Inoue, T. Trans-activation of the Tetrahymena ribozyme by its P2-2.1 domains. J. Biochem. (Tokyo) 123, 528–533 (1998).
Duhamel, J. et al. Secondary structure content of the HDV ribozyme in 95% formamide. Nucleic Acids Res. 24, 3911–3917 (1996).
Trang, P., Kilani, A., Kim, J. & Liu, F. A ribozyme derived from the catalytic subunit of RNase P from Escherichia coli is highly effective in inhibiting replication of herpes simplex virus 1. J. Mol. Biol. 301, 817–826 (2000).
Kilani, A.F. et al. RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture. J. Biol. Chem. 275, 10611–10622 (2000).
Dunn, W., Trang, P., Khan, U., Zhu, J. & Liu, F. RNase P-mediated inhibition of cytomegalovirus protease expression and viral DNA encapsidation by oligonucleotide external guide sequences. Proc. Natl. Acad. Sci. USA 98, 14831–14836 (2001).
Trang, P. et al. Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. J. Mol. Biol. 315, 573–586 (2002).
Trang, P. et al. Effective inhibition of human cytomegalovirus gene expression and replication by a ribozyme derived from the catalytic RNA subunit of RNase P from Escherichia coli. Proc. Natl. Acad. Sci. USA 97, 5812–5817 (2000).
Forster, A.C., Jeffries, A.C., Sheldon, C.C. & Symons, R.H. Structural and ionic requirements for self-cleavage of virusoid RNAs and trans self-cleavage of viroid RNA. Cold Spring Harb. Symp. Quant. Biol. 52, 249–259 (1987).
Haseloff, J. & Gerlach, W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Biotechnology 24, 264–269 (1992).
Hampel, A., Tritz, R., Hicks, M. & Cruz, P. 'Hairpin' catalytic RNA model: evidence for helices and sequence requirement for substrate RNA. Nucleic Acids Res. 18, 299–304 (1990).
Haseloff, J. & Gerlach, W.L. Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature 334, 585–591 (1988).
Sarver, N. et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222–1225 (1990).
Opalinska, J.B. & Gewirtz, A.M. Nucleic-acid therapeutics: basic principles and recent applications. Nat. Rev. Drug Discov. 1, 503–514 (2002).
Sullenger, B.A. & Gilboa, E. Emerging clinical applications of RNA. Nature 418, 252–258 (2002).
Rossi, J.J. The application of ribozymes to HIV infection. Curr. Opin. Mol. Ther. 1, 316–322 (1999).
Rossi, J.J. Therapeutic applications of catalytic antisense RNAs (ribozymes). Ciba Found. Symp. 209, 195–204 (1997).
Couture, L.A. & Stinchcomb, D.T. Anti-gene therapy: the use of ribozymes to inhibit gene function. Trends Genet. 12, 510–515 (1996).
Santoro, S.W. & Joyce, G.F. A general purpose RNA-cleaving DNA enzyme. Proc. Natl. Acad. Sci. USA 94, 4262–4266 (1997).
Santoro, S.W. & Joyce, G.F. Mechanism and utility of an RNA-cleaving DNA enzyme. Biochemistry 37, 13330–13342 (1998).
Khachigian, L.M. DNAzymes: cutting a path to a new class of therapeutics. Curr. Opin. Mol. Ther. 4, 119–121 (2002).
Emilsson, G.M. & Breaker, R.R. Deoxyribozymes: new activities and new applications. Cell Mol. Life Sci. 59, 596–607 (2002).
Cairns, M.J., Saravolac, E.G. & Sun, L.Q. Catalytic DNA: a novel tool for gene suppression. Curr. Drug Targets 3, 269–279 (2002).
Zhang, L. et al. Angiogenic inhibition mediated by a DNAzyme that targets vascular endothelial growth factor receptor 2. Cancer Res. 62, 5463–5469 (2002).
Wu, Y. et al. Inhibition of bcr-abl oncogene expression by novel deoxyribozymes (DNAzymes). Hum. Gene Ther. 10, 2847–2857 (1999).
Bernstein, E., Caudy, A.A., Hammond, S.M. & Hannon, G.J. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 409, 363–366 (2001).
Volpe, T.A. et al. Regulation of heterochromatic silencing and histone H3 lysine-9 methylation by RNAi. Science 297, 1833–1837 (2002).
Reinhart, B.J. & Bartel, D.P. Small RNAs correspond to centromere heterochromatic repeats. Science 297, 1831 (2002).
Hall, I.M. et al. Establishment and maintenance of a heterochromatin domain. Science 297, 2232–2237 (2002).
Schramke, V. & Allshire, R. Hairpin RNAs and retrotransposon LTRs effect RNAi and chromatin-based gene silencing. Science 301, 1069–1074 (2003).
Sledz, C.A., Holko, M., De Veer, M.J., Silverman, R.H. & Williams, B.R. Activation of the interferon system by short-interfering RNAs. Nat. Cell Biol. 5, 834–839 (2003).
Lee, Y. et al. The nuclear RNase III Drosha initiates microRNA processing. Nature 425, 415–419 (2003).
Schwarz, D.S. et al. Asymmetry in the assembly of the RNAi enzyme complex. Cell 115, 199–208 (2003).
Zeng, Y. & Cullen, B.R. Sequence requirements for micro RNA processing and function in human cells. RNA 9, 112–123 (2003).
Carrington, J.C. & Ambros, V. Role of microRNAs in plant and animal development. Science 301, 336–338 (2003).
Lim, L.P., Glasner, M.E., Yekta, S., Burge, C.B. & Bartel, D.P. Vertebrate microRNA genes. Science 299, 1540 (2003).
Hutvagner, G. & Zamore, P.D. RNAi: nature abhors a double-strand. Curr. Opin. Genet. Dev. 12, 225–232 (2002).
Doench, J.G., Petersen, C.P. & Sharp, P.A. siRNAs can function as miRNAs. Genes Dev. 17, 438–442 (2003).
Zeng, Y., Wagner, E.J. & Cullen, B.R. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell 9, 1327–1333 (2002).
Tuschl, T. Expanding small RNA interference. Nat. Biotechnol. 20, 446–448 (2002).
Zeng, Y. & Cullen, B.R. RNA interference in human cells is restricted to the cytoplasm. RNA 8, 855–860 (2002).
Michienzi, A., Cagnon, L., Bahner, I. & Rossi, J.J. Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Sci. USA 97, 8955–8960 (2000).
Grunweller, A. et al. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res. 31, 3185–3193 (2003).
Vickers, T.A. et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J. Biol. Chem. 278, 7108–7118 (2003).
Holen, T., Amarzguioui, M., Wiiger, M.T., Babaie, E. & Prydz, H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 30, 1757–1766 (2002).
Bohula, E.A. et al. The efficacy of small interfering RNAs targeted to the type 1 insulin-like growth factor receptor (IGF1R) is influenced by secondary structure in the IGF1R transcript. J. Biol. Chem. 278, 15991–15997 (2003).
Rossi, J.J. Ribozymes, genomics and therapeutics. Chem. Biol. 6, R33–R37 (1999).
Khvorova, A., Reynolds, A. & Jayasena, S.D. Functional siRNAs and miRNAs exhibit strand bias. Cell 115, 209–216 (2003).
Lee, N.S. et al. Functional colocalization of ribozymes and target mRNAs in Drosophila oocytes. FASEB J. 15, 2390–2400 (2001).
Lee, N.S., Bertrand, E. & Rossi, J. mRNA localization signals can enhance the intracellular effectiveness of hammerhead ribozymes. RNA 5, 1200–1209 (1999).
Castanotto, D., Scherr, M. & Rossi, J.J. Intracellular expression and function of antisense catalytic RNAs. Methods Enzymol. 313, 401–420 (2000).
Sullenger, B.A. Colocalizing ribozymes with substrate RNAs to increase their efficacy as gene inhibitors. Appl. Biochem. Biotechnol. 54, 57–61 (1995).
Kawasaki, H. & Taira, K. Short hairpin type of dsRNAs that are controlled by tRNA(Val) promoter significantly induce RNAi-mediated gene silencing in the cytoplasm of human cells. Nucleic Acids Res. 31, 700–707 (2003).
Giles, R.V. & Tidd, D.M. Increased specificity for antisense oligodeoxynucleotide targeting of RNA cleavage by RNase H using chimeric methylphosphonodiester/phosphodiester structures. Nucleic Acids Res. 20, 763–770 (1992).
Millington-Ward, S. et al. A mutation-independent therapeutic strategem for osteogenesis imperfecta. Antisense Nucleic Acid Drug. Dev. 9, 537–542 (1999).
Drenser, K.A., Timmers, A.M., Hauswirth, W.W. & Lewin, A.S. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa. Invest. Ophthalmol. Vis. Sci. 39, 681–689 (1998).
Lewin, A.S. et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat. Med. 4, 967–971 (1998).
Jackson, A.L. et al. Expression profiling reveals off-target gene regulation by RNAi. Nat. Biotechnol. 21, 635–637 (2003).
Chi, J.T. et al. Genome-wide view of gene silencing by small interfering RNAs. Proc. Natl. Acad. Sci. USA 100, 6343–6346 (2003).
Krieg, A.M. CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol. 20, 709–760 (2002).
Mirmohammadsadegh, A., Maschke, J., Basner-Tschakarjan, E., Bar, A. & Hengge, U.R. Induction of acute phase response genes in keratinocytes following exposure to oligodeoxynucleotides. J. Mol. Med. 80, 377–383 (2002).
Gewirtz, A.M. Oligonucleotide therapeutics: clothing the emperor. Curr. Opin. Mol. Ther. 1, 297–306 (1999).
Bridge, A.J., Pebernard, S., Ducraux, A., Nicoulaz, A.L. & Iggo, R. Induction of an interferon response by RNAi vectors in mammalian cells. Nat. Genet. 34, 263–264 (2003).
Matsukura, S., Jones, P.A. & Takai, D. Establishment of conditional vectors for hairpin siRNA knockdowns. Nucleic Acids Res. 31, e77 (2003).
Chen, Y., Stamatoyannopoulos, G. & Song, C.Z. Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res. 63, 4801–4804 (2003).
Chiu, Y.L. & Rana, T.M. siRNA function in RNAi: a chemical modification analysis. RNA 9, 1034–1048 (2003).
Fortes, P. et al. Inhibiting expression of specific genes in mammalian cells with 5′ end-mutated U1 small nuclear RNAs targeted to terminal exons of pre-mRNA. Proc. Natl. Acad. Sci. USA 100, 8264–8269 (2003).
Editorial. Whither RNAi? Nat. Cell. Biol. 5, 489–490 (2003).
Bartel, D. Whither RNAi? Nat. Cell. Biol. 5, 489–490 (2003).
Scott, W.G., Finch, J.T. & Klug, A. The crystal structure of an all-RNA hammerhead ribozyme. Nucleic Acids Symp. Ser. 34, 214–216 (1995).
Pley, H.W., Flaherty, K.M. & McKay, D.B. Three-dimensional structure of a hammerhead ribozyme. Nature 372, 68–74 (1994).
Hertel, K.J. et al. Numbering system for the hammerhead. Nucleic Acids Res. 20, 3252 (1992).
Acknowledgements
The authors were supported by grants from the National Institutes of Health, AI29329, AI42552 and NHL074704.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Scherer, L., Rossi, J. Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21, 1457–1465 (2003). https://doi.org/10.1038/nbt915
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt915
This article is cited by
-
Enhanced RNA knockdown efficiency with engineered fusion guide RNAs that function with both CRISPR-CasRx and hammerhead ribozyme
Genome Biology (2023)
-
Antisense RNA (asRNA) technology: the concept and applications in crop improvement and sustainable agriculture
Molecular Biology Reports (2023)
-
RNA Therapeutics: the Next Generation of Drugs for Cardiovascular Diseases
Current Atherosclerosis Reports (2022)
-
A T7 autogene-based hybrid mRNA/DNA system for long-term shRNA expression in cytoplasm without inefficient nuclear entry
Scientific Reports (2019)
-
A ribonucleoprotein octamer for targeted siRNA delivery
Nature Biomedical Engineering (2018)